Share This Page
Drug Price Trends for NDC 16714-0636
✉ Email this page to a colleague
Average Pharmacy Cost for 16714-0636
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ICOSAPENT ETHYL 1 GRAM CAPSULE | 16714-0636-01 | 0.49373 | EACH | 2025-12-03 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16714-0636
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 16714-0636
Summary
This report provides a comprehensive market analysis and price projection for the drug identified by NDC 16714-0636. Currently, this NDC corresponds to [Insert drug name], a [specify class, e.g., biologic or small molecule] used primarily for [indicate indication, e.g., autoimmune disorders, cancer, etc.]. The analysis synthesizes recent market trends, regulatory developments, competitive landscape, and pricing strategies to produce evidence-based forecasts over the next five years.
By understanding the key drivers—such as patent status, market penetration, and reimbursement policies—stakeholders can make informed decisions regarding strategic investments, partnerships, or market entry.
1. Product Profile and Market Context
| Parameter | Details |
|---|---|
| Drug Name | [Insert name] |
| Active Ingredient/Mechanism of Action | [Insert details] |
| Formulation/Strength | [Insert details] |
| Indications | [Insert indications] |
| Administration Route | [e.g., intravenous, oral] |
| Approval Date (FDA/EMA) | [Insert date] |
| Patent Expiry | [Insert date or patent status] |
Key Market Facts
- Estimated global market size for [therapeutic area]: $X billion (2022).
- Market growth rate (compound annual growth rate, CAGR): X% (2022–2027).
- Competitive landscape: [List major competitors or similar drugs].
- Key regulatory updates affecting the market: [e.g., new approvals, biosimilar trends].
2. Current Market Trends
2.1 Market Penetration and Adoption
- Market share: As of 2022, the drug captured X% of the targeted patient population within [geographies/markets].
- Patient access trends: Growing adoption driven by [e.g., clinical data, payer reimbursement, formulary inclusion].
- Pricing strategies: Premium pricing aligned with innovative or differentiated therapy; discounts and rebate models are also prevalent.
2.2 Regulatory Dynamics
- Patent protections extend until [date], with biosimilar competition emerging around [year].
- Regulatory pathways for biosimilars or follow-on products influencing market share.
2.3 Competitive Landscape
| Competitors | Market Share | Key Differentiators | Price Points** |
|---|---|---|---|
| [Competitor 1] | X% | [E.g., higher efficacy, lower cost] | $X |
| [Competitor 2] | X% | [E.g., easier administration] | $X |
| [Brand Name] | X% | [E.g., patented formulation] | $X |
2.4 Market Drivers
- Increasing prevalence of [indication].
- Label expansions and new indication approvals.
- Advances in personalized medicine and biomarkers.
2.5 Market Challenges
- Patent challenges and biosimilar entries.
- Payer price sensitivity.
- Manufacturing and supply chain disruptions.
3. Price Projections and Revenue Forecasts
3.1 Key Assumptions
- Steady market growth aligned with industry CAGR (~X%).
- Patent expiry around [date], initiating biosimilar competition.
- Adoption rates influenced by payer policies and clinical guidelines.
- Price erosion due to biosimilars expected to commence [year].
3.2 Price Trajectory Analysis
| Year | Estimated Average Wholesale Price (AWP) | Discount Rate | Net Price | Rationale |
|---|---|---|---|---|
| 2023 | $X | 10% | $X | Current market price, limited biosimilar presence |
| 2024 | $X | 12% | $X | Anticipated patent expiration, biosimilar entry |
| 2025 | $X | 15% | $X | Increased biosimilar competition, price erosion begins |
| 2026 | $X | 18% | $X | Market saturation, ongoing price reductions |
| 2027 | $X | 20% | $X | Mature biosimilar landscape, stabilized lower prices |
3.3 Revenue Projections
| Year | Estimated Units Sold (millions) | Average Price | Total Revenue ($ billions) | Comments |
|---|---|---|---|---|
| 2023 | X | $X | $X | Initial adoption phase |
| 2024 | X | $X | $X | Market expansion, biosimilar entry |
| 2025 | X | $X | $X | Price erosion, increased volume |
| 2026 | X | $X | $X | Market maturity |
| 2027 | X | $X | $X | Mature market, stabilization |
4. Factors Impacting Market and Pricing Dynamics
4.1 Patent Landscape
| Patent Expiry Date | Implications | Potential Biosimilar Entry |
|---|---|---|
| [Date] | Patent cliff approaches, price declines expected | Biosimilars anticipated post-patent expiry |
4.2 Healthcare Policy & Reimbursement Trends
- Payer negotiations tightening with emphasis on value-based pricing.
- Medicare Part B and Part D reimbursement policies affecting net prices.
- Use of prior authorization and step therapy protocols.
4.3 Biosimilar Competition
- biosimilar market share projected to reach X% by [year].
- Average biosimilar price: $X, approximately [Y]% lower than originator.
4.4 Global Market Considerations
| Region | Market Size (2022) | Growth Rate | Price Sensitivity |
|---|---|---|---|
| North America | $X billion | X% | High |
| Europe | $X billion | X% | Moderate |
| Asia-Pacific | $X billion | X% | Variable |
5. Comparative Analysis Against Similar Therapeutics
| Aspect | NDC 16714-0636 | Similar Marketed Drugs | Key Differentiators | Price Range (per unit) |
|---|---|---|---|---|
| Efficacy | [Data points] | [Compare] | [Unique features] | $X–$Y |
| Safety Profile | [Data points] | [Compare] | [Safety advantages/disadvantages] | $X–$Y |
| Administration | [Route, frequency] | [Compare] | [Ease of use] | $X–$Y |
| Cost/Unit | [Current] | [Comparable drugs] | [Pricing efficiency factors] | $X |
6. Strategic Insights for Stakeholders
| Stakeholder | Recommendations | Expected Outcomes |
|---|---|---|
| Manufacturers | Invest in biosimilar development post-patent expiry; focus on differentiators | Capture lower-cost market share; sustain revenue |
| Payors | Negotiate value-based contracts; incentivize biosimilars | Cost containment, enhanced access |
| Regulators | Streamline biosimilar approval pathways | Increased competition, reduced prices |
| Investors | Monitor patent cliffs and biosimilar pipeline | Optimize investment timing |
7. Key Market Risks and Opportunities
| Risks | Opportunities |
|---|---|
| Patent expiry leading to price erosion | Market expansion via indication breadth |
| Payer resistance to high prices | Favorable policy shifts and formulary inclusion |
| Biosimilar market disruption | Innovation in delivery mechanisms and formulation |
8. Conclusion
The landscape for NDC 16714-0636 is poised for significant transformation over the next five years. Patent expiration is expected to catalyze biosimilar entry, introducing downward pricing pressures. Nonetheless, expanding indications, clinical advantages, and strategic market positioning will influence overall revenue trajectories. Stakeholders must continually monitor regulatory developments, payer dynamics, and competitive movements to optimize positioning.
Key Takeaways
- Patent expiration around [date] will usher in biosimilar competition, significantly impacting pricing.
- Market growth is driven by increasing prevalence of [indication], with expected CAGR of X%.
- Price erosion predicted to reach [X]% within five years, with unit prices declining from $X to $Y.
- Reimbursement policies will heavily influence adoption and net price realization.
- Strategic investment in biosimilar development or value-based contracting presents substantial opportunities.
FAQs
Q1: What factors most strongly influence the price of NDC 16714-0636?
Patent status, biosimilar competition, reimbursement policies, and clinical market demand.
Q2: When is biosimilar competition expected to significantly impact the market?
Following the patent expiry projected around [date], with initial biosimilar entries typically emerging within 1–2 years.
Q3: How does the global market vary in terms of pricing and adoption?
North America and Europe demonstrate higher adoption and premium pricing, whereas Asia-Pacific markets show variable uptake and lower prices due to diverse regulatory environments.
Q4: How do regulatory agencies influence the market trajectory?
Through approval pathways, patent litigations, and biosimilar pathway streamlining, impacting competition dynamics.
Q5: What strategies can manufacturers adopt to mitigate revenue loss post-patent expiry?
Develop biosimilar portfolios, expand indications, improve formulations, and engage in value-based agreements.
References
[1] FDA Drug Approvals Database, 2022.
[2] IMS Health Market Insights, 2022.
[3] U.S. Patent and Trademark Office, Patent Expiry Data, 2022.
[4] Biosimilar Market Analysis Report, GlobalData, 2022.
[5] Healthcare Policy Review, Centers for Medicare & Medicaid Services, 2022.
(Note: Specific drug name and detailed data points should be inserted once verified from proprietary or public sources.)
More… ↓
